Cooley advised Isis Pharmaceuticals, Inc. on its Rule 144A offering of $500 million aggregate principal amount of convertible senior notes due 2021. The initial purchasers have purchased $15 million aggregate principal amount of convertible notes.

Isis is the leading company in antisense drug discovery and development; exploiting a proven, novel drug discovery platform designed to generate a pipeline of first-in-class drugs.

The Cooley team advising Isis Pharmaceuticals was led by partners Charlie Kim, Gian-Michele a Marca and Sean Clayton, and included associates Jon Russo, Jason Savich, Phillip McGill and Adrienne Directo. Critical support was also provided by partner Natasha Leskovsek (health care and life sciences regulatory); and partners Susan Cooper Philpot and Mark Windfeld-Hansen (tax).


Related Posts:

Leave a Reply